Researcher Profiles

Return to member profile

Rebecca Moss, MD

Publications since 2011

Cruz, J. E. Saksena, R. Jabbour, S. K. Nosher, J. L. Hermes-DeSantis, E. Moss, R. A. The Power of Genes: A Case of Unusually Severe Systemic Toxicity After Localized Hepatic Chemoembolization With Irinotecan-Eluted Microspheres for Metastatic Colon Cancer. Ann Pharmacother, 48:1646-1650, . (PMID: 25202035)

Herrigel, D. J. Moss, R. A. Diabetes mellitus as a novel risk factor for gastrointestinal malignancies. Postgrad Med, 126:106-118, . (PMID: 25414939)

Salgia, R. Patel, P. Bothos, J. Yu, W. Eppler, S. Hegde, P. Bai, S. Kaur, S. Nijem, I. Catenacci, D. V. Peterson, A. Ratain, M. J. Polite, B. Mehnert, J. M. Moss, R. A. Phase I Dose-Escalation Study of Onartuzumab as a Single Agent and in Combination with Bevacizumab in Patients with Advanced Solid Malignancies. Clin Cancer Res, 20:1666-1675, . (PMID: 24493831)

Khan, G. Moss, R. A. Braiteh, F. Saltzman, M. Proactive strategies for regorafenib in metastatic colorectal cancer: implications for optimal patient management. Cancer Manag Res, 6:93-103, . (PMID: 24623990, PMCID: PMC3949557)

Fine, R. L. Gulati, A. P. Krantz, B. A. Moss, R. A. Schreibman, S. Tsushima, D. A. Mowatt, K. B. Dinnen, R. D. Mao, Y. Stevens, P. D. Schrope, B. Allendorf, J. Lee, J. A. Sherman, W. H. Chabot, J. A. Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience. Cancer Chemother Pharmacol, 71:663-670, . (PMID: 23370660)

Gulati, A. P. Krantz, B. Moss, R. A. Moyal, W. N. Tsushima, D. A. Mowatt, K. B. Schreibman, S. Fine, R. L. Treatment of Multiple Endocrine Neoplasia 1/2 Tumors: Case Report and Review of the Literature. Oncology, 84:127-134, . (PMID: 23235517)

Burris, H. A. 3rd Dowlati, A. Moss, R. A. Infante, J. R. Jones, S. F. Spigel, D. R. Levinson, K. T. Lindquist, D. Gainer, S. D. Dar, M. M. Suttle, A. B. Ball, H. A. Tan, A. R. Phase I study of pazopanib in combination with Paclitaxel and Carboplatin given every 21 days in patients with advanced solid tumors. Mol Cancer Ther, 11:1820-1828, . (PMID: 22679111)

Moss, R. A. Moore, D. Mulcahy, M. F. Nahum, K. Saraiya, B. Eddy, S. Kleber, M. Poplin, E. A. A Multi-institutional Phase 2 Study of Imatinib Mesylate and Gemcitabine for First-Line Treatment of Advanced Pancreatic Cancer. Gastrointest Cancer Res, 5:77-83, . (PMID: 22888387, PMCID: PMC3415717)

Saraiya, B. Chugh, R. Karantza, V. Mehnert, J. Moss, R. A. Savkina, N. Stein, M. N. Baker, L. H. Chenevert, T. Poplin, E. A. Phase I study of gemcitabine, docetaxel and imatinib in refractory and relapsed solid tumors. Invest New Drugs, 30:258-265, . (PMID: 20697775)

Tunceroglu, A. Park, J. H. Balasubramanian, S. Poppe, M. Anker, C. J. Poplin, E. Moss, R. A. Yue, N. J. Carpizo, D. Gannon, C. J. Haffty, B. G. Jabbour, S. K. Dose-painted intensity modulated radiation therapy improves local control for locally advanced pancreas cancer. ISRN Oncol, 2012:572342, . (PMID: 23119186, PMCID: PMC3483817)

Jabbour, S. K. Patel, S. Herman, J. M. Wild, A. Nagda, S. N. Altoos, T. Tunceroglu, A. Azad, N. Gearheart, S. Moss, R. A. Poplin, E. Levinson, L. L. Chandra, R. A. Moore, D. F. Chen, C. Haffty, B. G. Tuli, R. Intensity-modulated radiation therapy for rectal carcinoma can reduce treatment breaks and emergency department visits. Int J Surg Oncol, 2012:891067, . (PMID: 22934164, PMCID: PMC3425793)

Mehnert, J. M. Tan, A. R. Moss, R. Poplin, E. Stein, M. N. Sovak, M. Levinson, K. Lin, H. Kane, M. Gounder, M. Lin, Y. Shih, W. J. White, E. Rubin, E. H. Karantza, V. Rationally designed treatment for solid tumors with MAPK pathway activation: a phase I study of paclitaxel and bortezomib using an adaptive dose-finding approach. Mol Cancer Ther, 10:1509-1519, . (PMID: 21680752, PMCID: PMC3155243)